CU22871A1 - Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal - Google Patents

Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal

Info

Publication number
CU22871A1
CU22871A1 CU1998183A CU1998183A CU22871A1 CU 22871 A1 CU22871 A1 CU 22871A1 CU 1998183 A CU1998183 A CU 1998183A CU 1998183 A CU1998183 A CU 1998183A CU 22871 A1 CU22871 A1 CU 22871A1
Authority
CU
Cuba
Prior art keywords
formulations
hbsag
antigens
mucosal
formulation
Prior art date
Application number
CU1998183A
Other languages
English (en)
Inventor
Gardon Daniel Octavio Palenzuela
Perez Enrique Iglesias
Diaz Dagmara Pichardo
Rubido Julio Cesar Aguilar
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1998183A priority Critical patent/CU22871A1/es
Priority to ARP990106037 priority patent/AR021414A1/es
Priority to DE1999632182 priority patent/DE69932182T2/de
Priority to EP19990957844 priority patent/EP1136077B1/en
Priority to US09/857,402 priority patent/US7374766B1/en
Priority to HK02101388.6A priority patent/HK1042424B/en
Priority to AT99957844T priority patent/ATE331528T1/de
Priority to ES99957844T priority patent/ES2264273T3/es
Priority to PT99957844T priority patent/PT1136077E/pt
Priority to PCT/CU1999/000006 priority patent/WO2000032229A1/es
Priority to CA 2352777 priority patent/CA2352777C/en
Priority to CNB998151912A priority patent/CN1191853C/zh
Priority to BRPI9915946-5A priority patent/BR9915946B1/pt
Publication of CU22871A1 publication Critical patent/CU22871A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención está relacionada con la rama de la medicina, particularmemte con las nuevas formulaciones de antígenos vacunales. El objetivo técnico que se persigue con la invención propuesta es precisamente el desarrollo de formulaciones capaces de potenciar la respuesta inmune a antígenos administrados por vía mucosal, minimizando el número de componentes de la formulación y generando potentes respuestas mucosales y sistemáticas mediante una interacción sinérgica entre los antígenos de la formulación. Estas formulaciones permiten a) ampliar el espectro de la respuesta inmune anti-hepatitis B, conteniendo como componentes fundamentales al HBsAg y al HBcAg o posibles derivados de los mismos, b) potenciar la respuesta al HBsAg con nucleocápsidas virales y c) generar vacunas combinadas por vía mucosal cuyo antígeno central es el HBsAg. Pueden introducirse además estabilizadores y preservos. Las formulaciones de esta invención son aplicables en la industria farmacéutica como formulaciones vacunales tanto para uso humano como veterinario.
CU1998183A 1998-12-02 1998-12-02 Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal CU22871A1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CU1998183A CU22871A1 (es) 1998-12-02 1998-12-02 Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
ARP990106037 AR021414A1 (es) 1998-12-02 1999-11-26 Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
DE1999632182 DE69932182T2 (de) 1998-12-02 1999-12-01 Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.
EP19990957844 EP1136077B1 (en) 1998-12-02 1999-12-01 Preparations containing virus-like particles as immunopotentiators administered through the mucosa
US09/857,402 US7374766B1 (en) 1998-12-02 1999-12-01 Compositions containing virus-like particles as immunopotentiators administered through the mucosa
HK02101388.6A HK1042424B (en) 1998-12-02 1999-12-01 Preparations containing virus-like particles as immunopotentiators administered through the mucosa
AT99957844T ATE331528T1 (de) 1998-12-02 1999-12-01 Präparationen, die virus-ähnliche partikel als immunpotentiatoren enthalten und durch die schleimhaut verabreicht werden.
ES99957844T ES2264273T3 (es) 1998-12-02 1999-12-01 Preparaciones que contienen particulas similares a virus como inmunopotenciadores administrados a traves de mucosas.
PT99957844T PT1136077E (pt) 1998-12-02 1999-12-01 Preparacoes que contem particulas do tipo de virus como imunoestimulantes administrados atraves da mucosa
PCT/CU1999/000006 WO2000032229A1 (es) 1998-12-02 1999-12-01 Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
CA 2352777 CA2352777C (en) 1998-12-02 1999-12-01 Preparations containing virus-like particles as immunopotentiators administered through the mucosa
CNB998151912A CN1191853C (zh) 1998-12-02 1999-12-01 通过粘膜给药的含有作为免疫强化剂的病毒样颗粒的制剂
BRPI9915946-5A BR9915946B1 (pt) 1998-12-02 1999-12-01 formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1998183A CU22871A1 (es) 1998-12-02 1998-12-02 Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal

Publications (1)

Publication Number Publication Date
CU22871A1 true CU22871A1 (es) 2003-10-21

Family

ID=5459504

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1998183A CU22871A1 (es) 1998-12-02 1998-12-02 Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal

Country Status (13)

Country Link
US (1) US7374766B1 (es)
EP (1) EP1136077B1 (es)
CN (1) CN1191853C (es)
AR (1) AR021414A1 (es)
AT (1) ATE331528T1 (es)
BR (1) BR9915946B1 (es)
CA (1) CA2352777C (es)
CU (1) CU22871A1 (es)
DE (1) DE69932182T2 (es)
ES (1) ES2264273T3 (es)
HK (1) HK1042424B (es)
PT (1) PT1136077E (es)
WO (1) WO2000032229A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031079D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003277448A1 (en) 2002-10-17 2004-05-04 Enzo Therapeutics, Inc. Transmucosal administration of aggregated antigens
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
EP3344293A4 (en) 2015-09-04 2019-01-16 Inventprise, LLC. VLP-STABILIZED VACCINE COMPOSITIONS
US10159728B2 (en) 2015-09-10 2018-12-25 Inventprise, Llc Multivalent VLP conjugates
EA201892212A1 (ru) 2016-03-31 2019-03-29 Сентро Де Инхеньерия Хенетика И Биотекнолохия Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物
MX2020013240A (es) * 2018-06-05 2021-05-12 Toko Yakuhin Kogyo Kk Sistema de administracion transnasal de la vacuna contra la hepatitis b.
US11389519B2 (en) 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
EP4034158A4 (en) * 2019-09-23 2023-10-04 Ascendo Biotechnology, Inc. BIODEGRADABLE NANOCOMPLEX VACCINE, METHODS FOR SUPPRESSING HEPATITIS B VIRUS REPLICATION AND SECRETION OF HEPATITIS B VIRUS SURFACE ANTIGEN
CN111450245A (zh) * 2020-04-29 2020-07-28 艾棣维欣(苏州)生物制药有限公司 一种乙型肝炎治疗疫苗及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547368A (en) * 1983-12-20 1985-10-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitis B core antigen vaccine made by recombinant DNA
US4882145A (en) 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US6319501B1 (en) * 1990-07-19 2001-11-20 Health Research, Inc. Method of immunizing against hepatitis B virus
US5840303A (en) 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP3738395B2 (ja) * 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU5679394A (en) 1992-11-25 1994-06-22 International Biotechnology Laboratories, Inc. Hepatitis b virus vaccines
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732605B1 (fr) 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
US6153392A (en) 1997-07-30 2000-11-28 Bionova Corporation Devices and methods comprising an HBcAg from hepatitis B virus
CA2302545C (en) 1997-09-05 2012-04-03 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
WO2000032229A1 (es) 2000-06-08
PT1136077E (pt) 2006-10-31
BR9915946A (pt) 2001-08-21
ATE331528T1 (de) 2006-07-15
DE69932182D1 (de) 2006-08-10
CN1332637A (zh) 2002-01-23
CN1191853C (zh) 2005-03-09
CA2352777A1 (en) 2000-06-08
ES2264273T3 (es) 2006-12-16
BR9915946B1 (pt) 2010-12-14
AR021414A1 (es) 2002-07-17
EP1136077A1 (en) 2001-09-26
US7374766B1 (en) 2008-05-20
DE69932182T2 (de) 2007-05-10
EP1136077B1 (en) 2006-06-28
HK1042424B (en) 2007-05-11
CA2352777C (en) 2009-09-08
HK1042424A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
SE8604007D0 (sv) Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
LU91323I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
CO4910170A1 (es) Vacunas
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
ES2265672T3 (es) Micelas mixtas de lipopeptidos para la induccion de una respuesta inmunitaria.
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
DK0588578T3 (da) Immunogener
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
Poovorawan et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais
ECSP13012476A (es) Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
Harmon et al. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines
AR023534A1 (es) Vacuna.
BR112012014689B1 (pt) composição imunogênica
Gonçalves et al. Effect of etching time and light source on the bond strength of metallic brackets to ceramic
CU22740A1 (es) Formulación de ácidos nucleicos y acemanano
Henao-Restrepo et al. Measles aerosol vaccine project
CU23011A1 (es) Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
Glück et al. Human rabies immunoglobulin assayed by the rapid fluorescent focus inhibition test suppresses active rabies immunization
MX9303771A (es) Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno